【花旗:中国生物制药(01177.HK)收购礼新医药为业界首宗“中国对中国”并购 评级“买入”】智通财经APP获悉,花旗

智通财经
Jul 16, 2025
【花旗:中国生物制药(01177.HK)收购礼新医药为业界首宗“中国对中国”并购 评级“买入”】智通财经APP获悉,花旗发布研报称,中国生物制药(01177.HK)收购礼新医药将进一步扩展中生制药创新产品线。 该行指,礼新医药拥宝贵创新产品线,包括已授权默沙东的LM-299(PD-1/VEGF)、已授权阿斯利康的LM-305(GPRC5D ADC)、LM-108(CCR8单抗)及LM-302(CLDN18.2 ADC)。 该行亦认为交易是中国制药业一个里程碑,因这是首宗“中国对中国”并购,目前予中生制药“买入”评级及6.2港元目标价。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10